President Trump announced that the Food and Drug Administration granted emergency use authorization to treat COVID-19 patients with plasma from people who have recovered from the virus, based on 'promising' results.
President Donald Trump, left, FDA Commissioner Stephen Hahn, right, and Health and Human Services Secretary Alex Azar, center, announced at a news conference on Sunday that the FDA issued emergency use authorization for convalescent plasma as a COVID-19 treatment.
Convalescent plasma, Hahn explained, is the liquid portion of the blood that contains the antibodies an individual develops in response to an infection and can be given to patients currently fighting that virus. He said this treatment has long been a part of the infectious disease arsenal. "We dream, in drug development, of something like a 35% mortality reduction," Azar said."This is a major advance in the treatment of patients."
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Authorizes Convalescent Plasma for Covid-19 UseThe emergency-use authorization comes after preliminary studies supported the benefits of the antibody-rich plasma taken from recovered Covid-19 patients.
Read more »
Trump repeats chloroquine COVID-19 claims, accuses FDA of sabotaging vaccine trialsU.S. President Donald Trump suggested that the 'deep state' at the FDA deliberately delayed developing a COVID-19 vaccine.
Read more »
Trump Accuses FDA Of 'Deep State' Conspiracy Against Him Over COVID-19 Vaccine TestingNancy Pelosi says accusation goes 'beyond the pale,' even for Trump, 'in terms of how he would jeopardize' Americans' health to serve his reelection.
Read more »
Trump and FDA announce new method to treat hospitalized COVID-19 patientsThe president said the new, expedited method of treatment has led to a reduced mortality rate by 35 percent in coronavirus patients.
Read more »
Trump announces authorisation of plasma treatment for Covid-19White House officials suggest that the Food and Drug Administration is creating politically motivated delays.
Read more »